Traded Oct 15 – Oct 16, 2026 · largest single transaction ~$285
Show all 2 transactions
Oct 15, 2026~$190 · 200 sh @ $0.95
DetailsOfficial recordOct 16, 2026~$285 · 300 sh @ $0.95
DetailsOfficial record
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
BCDA · NASDAQ · Biological Products, (No Diagnostic Substances)
Biocardia (BCDA) · oqro.io/stocks/BCDA · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$0.785+0.0124 (+1.60%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
30 routine filings (option exercises, shares withheld for taxes, grants, gifts) are not listed here. Show them
Traded Oct 15 – Oct 16, 2026 · largest single transaction ~$285
Oct 15, 2026~$190 · 200 sh @ $0.95
DetailsOfficial recordOct 16, 2026~$285 · 300 sh @ $0.95
DetailsOfficial recordInsider buying
Traded Sep 29 · filed 1 day later
Since the trade −23.8% · S&P 500 −9.7% · to Nov 20
Bought 34% below the 52-week high, RSI 45, 8% under its 200-day average, 19 points behind the S&P 500 over 3 months
The CEO of Biocardia paid $1K out of pocket for Biocardia shares.
Insider buying
Traded Sep 23 · filed 1 day later
Since the trade −25.2% · S&P 500 −10.2% · to Nov 20
Bought 33% below the 52-week high, RSI 47, 6% under its 200-day average
The CEO of Biocardia paid $2K out of pocket for Biocardia shares.
Insider buying
Traded Sep 3 · filed 2 days later
Since the trade −28.0% · S&P 500 −10.8% · to Nov 20
Bought 52% below the 52-week high, RSI 57, 4% under its 200-day average, 16 points ahead of the S&P 500 over 3 months
The CEO of Biocardia paid $872 out of pocket for Biocardia shares.
Insider buying
2 days before an 8-KTraded Aug 17 · filed 1 day later
Since the trade −16.5% · S&P 500 −10.7% · to Nov 20
Bought 59% below the 52-week high, RSI 52, 18% under its 200-day average, 11 points behind the S&P 500 over 3 months
Insider buying
6 days before an 8-KTraded Aug 13 · filed the same day
Since the trade −15.5% · S&P 500 −11.3% · to Nov 20
Bought 59% below the 52-week high, RSI 52, 20% under its 200-day average, 18 points behind the S&P 500 over 3 months
Insider buying
14 days before resultsTraded Jul 29 · filed 1 day later
Since the trade +1.5% · S&P 500 −5.4% · to Nov 20
Bought at the 52-week low, RSI 36, 35% under its 200-day average, 35 points behind the S&P 500 over 3 months
Insider buying
Traded Jul 17 · filed 3 days later
Since the trade −4.9% · S&P 500 −7.2% · to Nov 20
Bought within 4% of the 52-week low, RSI 38, 32% under its 200-day average, 37 points behind the S&P 500 over 3 months
The CEO of Biocardia paid $415 out of pocket for Biocardia shares. 1 other person at Biocardia bought some too, in the same month.
Traded Jul 14 – Jul 15, 2026 · largest single transaction ~$2.5K
Jul 14, 2026~$2.5K · 2,800 sh @ $0.88
DetailsOfficial recordTraded Jul 8 – Jul 10, 2026 · largest single transaction ~$5.3K
Jul 8, 2026~$5.3K · 5,500 sh @ $0.97
DetailsOfficial recordTraded Jun 22 – Jun 23, 2026 · largest single transaction ~$65K
Jun 22, 2026~$65K · 70K sh @ $0.92
DetailsOfficial recordTraded Jun 17 – Jun 18, 2026 · largest single transaction ~$1.3K
Jun 17, 2026~$1.3K · 1,500 sh @ $0.85
DetailsOfficial recordInsider buying
3 days before an 8-KTraded Jun 9 · filed the same day
Since the trade −8.7% · S&P 500 −6.4% · to Nov 20
Bought at the 52-week low, RSI 38, 34% under its 200-day average, 41 points behind the S&P 500 over 3 months
Traded May 18 – May 20, 2026 · largest single transaction ~$5.2K
May 20, 2026~$1.4K · 1,500 sh @ $0.92
DetailsOfficial recordInsider buying
Traded May 15 · filed the same day
Since the trade −22.3% · S&P 500 −6.7% · to Nov 20
Bought at the 52-week low, RSI 33, 27% under its 200-day average, 20 points behind the S&P 500 over 3 months
The CEO of Biocardia paid $5.2K out of pocket for Biocardia shares.
Insider buying
Traded Apr 29 · filed the same day
Since the trade −28.6% · S&P 500 −3.1% · to Nov 20
Bought within 1% of the 52-week low, RSI 36, 25% under its 200-day average, 18 points behind the S&P 500 over 3 months
The CEO of Biocardia paid $5.5K out of pocket for Biocardia shares.
Traded Apr 20 – Apr 21, 2026 · largest single transaction ~$738
Apr 20, 2026~$738 · 600 sh @ $1.23
DetailsOfficial recordTraded Mar 24 – Mar 25, 2026 · largest single transaction ~$744
Mar 24, 2026~$744 · 600 sh @ $1.24
DetailsOfficial recordInsider buying
Traded Feb 4 · filed the same day
Since the trade −28.0% · S&P 500 +0.5% · to Nov 20
Bought at the 52-week low, RSI 28, 38% under its 200-day average, 22 points behind the S&P 500 over 3 months
The CEO of Biocardia paid $5.7K out of pocket for Biocardia shares.
Traded Jan 20 – Jan 21, 2026 · largest single transaction ~$792
Jan 20, 2026~$792 · 600 sh @ $1.32
DetailsOfficial recordTraded Dec 16 – Dec 17, 2025 · largest single transaction ~$1.2K
Dec 17, 2025~$1.2K · 900 sh @ $1.30
DetailsOfficial recordInsider buying
3 insiders in a week, 8th time since 2007Traded Sep 19, 2025 · filed 4 days later
Since the trade −32.3% · S&P 500 +3.9% · to Nov 20
A Biocardia director paid $498K out of pocket for Biocardia shares. 2 other people at Biocardia bought some too, in the same month. Shares held went up 207% with this purchase.
Insider buying
3 insiders in a week, 8th time since 2007Traded Sep 19, 2025 · filed 4 days later
Since the trade −32.3% · S&P 500 +3.9% · to Nov 20
A Biocardia director paid $360K out of pocket for Biocardia shares. 2 other people at Biocardia bought some too, in the same month. Shares held went up 83% with this purchase.
Insider buying
3 insiders in a week, 8th time since 2007Traded Sep 19, 2025 · filed 4 days later
Since the trade −32.3% · S&P 500 +3.9% · to Nov 20
The CEO of Biocardia paid $60K out of pocket for Biocardia shares. 2 other people at Biocardia bought some too, in the same month. Shares held went up 28% with this purchase.
Insider buying
Traded Aug 22, 2025 · filed 3 days later
Since the trade −58.9% · S&P 500 +6.9% · to Nov 20
The CEO of Biocardia paid $1.3K out of pocket for Biocardia shares. 2 other people at Biocardia bought some too, in the same month.
Traded Aug 12 – Aug 13, 2025 · largest single transaction ~$700
Aug 13, 2025~$183 · 100 sh @ $1.83
DetailsOfficial recordJul 15, 2026~$1.3K · 1,500 sh @ $0.86
DetailsOfficial recordJul 9, 2026~$900 · 1,000 sh @ $0.90
DetailsOfficial recordJul 10, 2026~$940 · 1,000 sh @ $0.94
DetailsOfficial recordJul 8, 2026~$5.2K · 5,400 sh @ $0.9645
DetailsOfficial recordJun 23, 2026~$39K · 39K sh @ $1.00
DetailsOfficial recordJun 18, 2026~$768 · 800 sh @ $0.96
DetailsOfficial recordMay 19, 2026~$190 · 200 sh @ $0.95
DetailsOfficial recordMay 18, 2026~$5.2K · 5,700 sh @ $0.92
DetailsOfficial recordApr 21, 2026~$492 · 400 sh @ $1.23
DetailsOfficial recordMar 25, 2026~$366 · 300 sh @ $1.22
DetailsOfficial recordJan 21, 2026~$402 · 300 sh @ $1.34
DetailsOfficial recordDec 16, 2025~$274 · 200 sh @ $1.37
DetailsOfficial recordAug 12, 2025~$700 · 400 sh @ $1.75
DetailsOfficial record29 open-market purchases and 0 open-market sales by insiders of BCDA between Feb 22, 2026 and today, placed against the company's last 4 earnings releases. The latest on file was filed Nov 12, 2026.
PurchaseSale30 days before a release30 days after
| Earnings release | 30 days before | On the day | 30 days after |
|---|---|---|---|
| Nov 12, 2026 | 2 purchases | None | None |
| Aug 12, 2026 | 4 purchases | None | 3 purchases |
| May 15, 2026 | 3 purchases | 1 purchase | 4 purchases |
| Mar 24, 2026 | None | 1 purchase | 3 purchases |
Companies set trading windows, which usually close shortly before results and reopen after them, and insiders may trade under 10b5-1 plans adopted months earlier. A date alone does not show what a person knew or why they traded. Past release dates are the dates the company filed its 8-K with Item 2.02. An upcoming date, when one is mentioned, comes from the data provider's earnings calendar (Finnhub): it is not a company filing, it is not estimated by OQRO, and it may change. Open-market purchases and sales as reported on Form 4. Largest purchases around earnings, all companies